Porton Down, UK, 3 December 2010: GW Pharmaceuticals (AIM: GWP) today announces that it has appointed Peel Hunt Limited as Nominated Adviser and broker to the Company with immediate effect.... more
Porton Down, UK; 29 November 2010: GW Pharmaceuticals plc (AIM: GWP) today announces that its Managing Director, Justin Gover will be speaking at the 22nd Annual Piper Jaffray Health Care Conference i... more
Porton Down, UK, 23 November 2010: GW Pharmaceuticals plc (AIM: GWP), the specialty pharmaceutical company focused on cannabinoid science, announces its preliminary results for the year ended 30 Septe... more
Porton Down, UK; 23 November 2010: GW Pharmaceuticals plc (AIM: GWP) today announces the initiation of the Phase III clinical trials programme of Sativex® in the treatment of pain in patients with adv... more
Porton Down, UK, 3 November 2010: GW Pharmaceuticals plc (AIM: GWP) today announces that the New Zealand regulatory authority, MedSafe, has approved Sativex® as a treatment for the relief of spasticit... more
Porton Down, UK, 21 October 2010: GW Pharmaceuticals plc (AIM: GWP) will be announcing its preliminary financial results for the year end 30 September 2010 on Tuesday 23 November 2010.... more
Porton Down, UK, 14 October 2010: GW Pharmaceuticals plc (AIM: GWP) is pleased to note today’s announcement from marketing partner, Almirall, S.A., that efficacy data from three Phase III trials of Sa... more
Porton Down, UK, 30 September 2010: GW Pharmaceuticals plc (GWP:AIM) announces that it has commenced the first of a programme of Phase IIa exploratory clinical trials exploring GW’s cannabinoids as p... more
Porton Down, UK, 22 September 2010: GW Pharmaceuticals plc (GWP:AIM) announces that results of a Phase II clinical study of Sativex® (delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)) in the t... more
Porton Down, UK; Toronto, Canada – August 31, 2010 – GW Pharmaceuticals plc (AIM: GWP) and Bayer Inc., a subsidiary of Bayer AG, today announced that Health Canada has approved Sativex® [delta-9-tetra... more
• Spanish health authorities grant regulatory approval for Sativex®, the first new treatment for MS-related spasticity in decades • Launch expected 4th Quarter 2010 • Application submitted unde... more
Porton Down, UK, 27 July 2010: GW Pharmaceuticals plc (AIM: GWP) today announces the appointment of Tom Lynch as a non-executive director with immediate effect.... more
In response to a story in a regional UK media outlet yesterday, GW wishes to make the following clarification: ... more
London, UK; Tokyo, Japan; June 30 2010: GW Pharmaceuticals plc (AIM: GWP) and Otsuka Pharmaceutical Co., Ltd. today announce that they have signed a three year extension to their global cannabinoid re... more
Porton Down, UK, 22 June 2010: GW Pharmaceuticals plc (AIM: GWP) announces that its Managing Director, Justin Gover will be presenting at the 5th Annual Piper Jaffray Europe Healthcare Conference in L... more
Porton Down, UK, 21 June 2010: GW Pharmaceuticals plc (GWP:AIM) today announces the UK launch of Sativex®, its Oromucosal Spray for the treatment of spasticity due to Multiple Sclerosis (MS). Sativex®... more
Porton Down, UK, 20 May 2010: GW Pharmaceuticals plc (AIM: GWP), the specialty pharmaceutical company focused on cannabinoid science, announces its interim results for the six months ended 31 March 20... more
Porton Down, UK; 23 March 2010: GW Pharmaceuticals plc (AIM: GWP) today announced preliminary results of a Phase IIb dose-ranging trial evaluating the efficacy and safety of Sativex® in the treatment ... more
Porton Down, UK, 18 March 2010: GW Pharmaceuticals plc (GWP:AIM) today provides an update on the progress of its regulatory submission for Sativex® Oromucosal Spray for the treatment of the symptoms o... more
